A study in healthy volunteers to assess effect of AZD6765 on Midazolam blood levels
Study identifier:D6702C00008
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I Open-label, Fixed Sequence Study to Determine the Effect of Multiple Intravenous Doses of AZD6765 on the Pharmacokinetics of Oral Midazolam (CYP3A4 Substrate) in Healthy Subjects
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD6765, midazolam
Sex
All
Actual Enrollment
46
Study type
Interventional
Age
18 Years - 55 Years
Date
Study Start Date: 01 Feb 2010
Primary Completion Date: 01 May 2010
Study Completion Date: 01 May 2010
Study design
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other
Verification:
Verified 01 Oct 2014 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 midazolam + AZD6765 IV solution | Drug: AZD6765 IV solution |
| Active Comparator: 2 | - |
Contacts
Investigators
Principal Investigator
Willie Earley
AstraZeneca
